Stroke recovery profile and the modified Rankin assessment

被引:92
作者
Lai, SM
Duncan, PW
机构
[1] Univ Kansas, Med Ctr, Dept Prevent Med, Kansas City, KS 66160 USA
[2] Univ Kansas, Med Ctr, Ctr Aging, Kansas City, KS 66103 USA
[3] Univ Kansas, Med Ctr, Dept Hlth Policy & Management, Kansas City, KS 66103 USA
[4] Dept Vet Affairs Med Ctr, Kansas City, MO USA
关键词
stroke recovery; higher-level functioning; utility assessment;
D O I
10.1159/000054754
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and Purpose: The purpose of th is study was to examine the relationship between the Modified Rankin Scale (MRS) and poststroke recovery in neurological deficits, activities of daily living (ADL), higher level of physical and social functioning and the patients' preference for health state. Methods: Four hundred and fifty-nine participants in the Kansas City Stroke Study were prospectively assessed for measures of MRS, NIH Stroke Scale (NIHSS), Barthel ADL, SF-36 physical functioning, SF-36 social functioning, and Time Trade-Off [TTO]. ANOVA and Bonferroni multiple comparisons were used to examine any differences in 3-month scores of NIHSS, Barthel ADL, SF-36 physical functioning, SF-36 social functioning and TTO between levels of the MRS. In addition, SF-36 physical functioning, SF-36 social functioning and TTO were characterized in patients who demonstrated improvement in global MRS outcome and also achieved a Barthel index (BI) greater than or equal to 95 at 3 months after stroke. Results: Two hundred and eighty patients (62%) shifted at least one grade in MRS from baseline to 3 months after stroke. Only 67 or 194 patients were considered to have a favorable outcome using MRS 0/1 or MRS 0/1/2, respectively, as criteria. Mean 3-month NIHSS and Barthel ADL scores were not significantly different between Rankin 0/1 and 2, but they were significantly different among Rankin 3, 4 and 5 (all p < 0.05). Mean 3-month scores of physical functioning and SF-36 social functioning were significantly different among Rankin 0/1, 2, 3 and 4 (all pairwise p < 0.05). Proportions of patients who achieved NIHSS less than or equal to1 or BI greater than or equal to 95 decreased as MRS grades worsened. In patients who showed improvement in MRS global outcome and also achieved BI greater than or equal to 95, mean scores on TTO were similar. Conclusions: Definition of favorable outcomes should include transition in the Modified Rankin score rather than MRS dichotomized as 0/1 or 0/1/2 because patients with transition in MRS scores have improvement in ADL, increased higher level of functioning and higher utility for health state. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:26 / 30
页数:5
相关论文
共 20 条
[1]   Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke - A randomized controlled trial [J].
Adams, HP ;
Woolson, RF ;
Helgason, C ;
Karanjia, PN ;
Gordon, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (16) :1265-1272
[2]  
[Anonymous], J NEUROLOGIC REHABIL
[3]  
Asher H. B., 1988, CAUSAL MODELING
[4]   MEASUREMENTS OF ACUTE CEREBRAL INFARCTION - A CLINICAL EXAMINATION SCALE [J].
BROTT, T ;
ADAMS, HP ;
OLINGER, CP ;
MARLER, JR ;
BARSAN, WG ;
BILLER, J ;
SPILKER, J ;
HOLLERAN, R ;
EBERLE, R ;
HERTZBERG, V ;
RORICK, M ;
MOOMAW, CJ ;
WALKER, M .
STROKE, 1989, 20 (07) :864-870
[5]   Termination of acute stroke studies involving selfotel treatment [J].
Davis, SM ;
Albers, GW ;
Diener, HC ;
Lees, KR ;
Norris, J .
LANCET, 1997, 349 (9044) :32-32
[6]   THE CLINICAL MEANING OF RANKIN HANDICAP GRADES AFTER STROKE [J].
DEHAAN, R ;
LIMBURG, M ;
BOSSUYT, P ;
VANDERMEULEN, J ;
AARONSON, N .
STROKE, 1995, 26 (11) :2027-2030
[7]  
Franke CL, 1996, ACTA NEUROL SCAND, V93, P56
[8]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[9]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[10]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017